Description
Humana Press Multi-Drug Resistance in Cancer 1st Editon 2012 Softbound by Jun Zhou
Chemotherapy is one of the major treatment options for cancer patients; however, the efficacy of chemotherapeutic management of cancer is severely limited by multidrug resistance, in that cancer cells become simultaneously resistant to many structurally and mechanistically unrelated drugs. In the past three decades, a number of mechanisms by which cancer cells acquire multidrug resistance have been discovered. In addition, the development of agents or strategies to overcome resistance has been the subject of intense study. This book contains comprehensive and up-to-date reviews of multidrug resistance mechanisms, from over-expression of ATP-binding cassette drug transporters such as P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance p- tein to the drug ratio-dependent antagonism and the paradigm of cancer stem cells. The book also includes strategies to overcome multidrug resistance, from the development of compounds that inhibit drug transporter function to the modulation of transporter expression. In addition, this book contains techniques for the detection and imaging of drug transporters, methods for the investigation of drug resistance in animal models, and strategies to evaluate the efficacy of resistance reversal agents. The book intends to provide a state-of-the-art collection of reviews and methods for both basic and clinician investigators who are interested in cancer multidrug resistance mechanisms and reversal strategies. Tianjin, China Jun Zhou v Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix 1 Multidrug Resistance in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Bruce C. Baguley 2 Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets . . . . . . . . . . . . . . . . . . . . . . . . . . Multidrug Resistance in Cancer.- Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets.- Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer.- Mechanisms of Multidrug Resistance in Cancer.- Molecular Mechanisms of Drug Resistance in Single-Step and Multi-Step Drug-Selected Cancer Cells.- Pharmacogenetics of ATP-Binding Cassette Transporters and Clinical Implications.- Flow Cytometric Evaluation of Multidrug Resistance Proteins.- Targeted Chemotherapy in Drug-Resistant Tumors, Noninvasive Imaging of P-Glycoprotein-Mediated Functional Transport in Cancer, and Emerging Role of Pgp in Neurodegenerative Diseases.- Epigenetic Regulation of Multidrug Resistance 1 Gene Expression: Profiling CpG Methylation Status Using Bisulphite Sequencing.- Expression and Function of P-Glycoprotein in Normal Tissues: Effect on Pharmacokinetics.- Molecular Mechanism of ATP-Dependent Solute Transport by Multidrug Resistance-Associated Protein 1.- Impact of Breast Cancer Resistance Protein on Cancer Treatment Outcomes.- Drug Ratio-Dependent Antagonism: A New Category of Multidrug Resistance and Strategies for Its Circumvention.- Reversing Agents for ATP-Binding Cassette Drug Transporters.- Overcoming Multidrug Resistance in Cancer: Clinical Studies of P-Glycoprotein Inhibitors.- Pharmacokinetic and Pharmacodynamic Implications of P-Glycoprotein Modulation.- Examination of CYP3A and P-Glycoprotein-Mediated Drug–Drug Interactions Using Animal Models.- Generating Inhibitors of P-Glycoprotein: Where to, Now?.- Immunosuppressors as Multidrug Resistance Reversal Agents.- Overcoming Multidrug Resistance by RNA Interference.- Circumventing Tumor Resistance to Chemotherapy by Nanotechnology.